STUDY QUESTION: In women undergoing IVF or ICSI cycles, do recombinant gonadotrophins differ from urinary-derived highly purified human menopausal gonadotropin (HP-hMG) or highly purified follicle-stimulating hormone (HP-FSH) in the total amount of gonadotrophins required to reach a live birth?
MAIN RESULTS AND THE ROLE OF CHANCE:
A total of 28 studies with 7553 women were included in this review, of which 24 studies provided information on the total amount of gonadotrophins per woman who started an IVF/ICSI cycle. The total amount of gonadotrophins varied significantly between studies. The MDs in total amount were −37 IU (seven studies; N = 3220; 95% CI, −115 to 41; I 2 = 68%) for rFSH versus HP-hMG and −31 IU (17 studies; N = 3629; 95% CI, −290 to 228; I 2 = 97%) for rFSH versus HP-FSH. For rFSH versus HP-hMG, the RR for clinical pregnancy, live birth and cumulative live birth were 0.90 (95% CI, 0.81-1.00), 0.88 (95% CI, 0.78-0.99) and 0.91 (95% CI, 0.80-1.04), respectively. For rFSH versus HP-FSH, the RR for clinical pregnancy and live birth were 1.03 (95% CI, 0.94-1.13) and 1.03 (95% CI, 0.90-1.18), respectively; the data on cumulative live birth rate were lacking. The estimated difference in mean gonadotrophin amount per extra live birth was 789 IU (95% CI, −9.5 to 1570) for rFSH versus HP-hMG and −365 IU (95% CI, −2675 to 1945) for rFSH versus HP-FSH.
LIMITATIONS, REASONS FOR CAUTION:
There was severe heterogeneity in the total amount of gonadotrophins between studies. A small fraction of women did not start gonadotrophin treatment; this was usually not accounted for in the provided mean amount of gonadotrophins per study and might have affected the averaged total amount of gonadotrophins but is unlikely to have affected the differences in the amount between rFSH and HP-hMG or HP-FSH. 
Introduction
Ovarian stimulation with gonadotrophins to induce the development of multiple follicles is the first phase of most ART (Macklon et al., 2006) . At present, gynecologists can choose between three commercially available gonadotrophins for ovarian stimulation in IVF/ICSI: rFSH, highly purified (HP)-hMG and HP-FSH.
Recombinant FSH (rFSH) is manufactured by recombinant DNA technology using a Chinese hamster ovary cell line transfected with the genes encoding human FSH (follitropin a and follitropin b) or derived from a cell line of human fetal retinal origin (FE 999049) . It has 99% purity, does not contain any LH activity and is very similar to natural FSH (Out et al., 1995; Olsson et al., 2014) . HP urinary gonadotrophins (HP-hMG and HP-FSH) are derived from urine of postmenopausal women. HP-hMG contains <5% of co-purified proteins and a 1:1 ratio of FSH and LH bioactivity and due to purification steps HP-FSH contains <0.1 IU LH and <5% of co-purified proteins (Lunenfeld and Lunenfeld, 1997; Wolfenson et al., 2005) .
The various gonadotrophin products are heterogeneous in isoform composition. The urinary preparations have more acidic isoforms compared to the recombinant products (Lispi et al., 2006) . Basic FSH isoforms have a high receptor affinity in vitro and a short halflife in vivo compared to acidic FSH isoforms (Practice Committee of American Society for Reproductive Medicine, Birmingham, Alabama, 2008) . It has been suggested that due to the lower acidity rFSH might be more biopotent in vivo and that, as a consequence, a lower total dose and less stimulation days compared to highly purified urinary-derived gonadotrophins would be required (Andersen and Ezcurra, 2011) .
It has been widely discussed in the literature that the differences in live birth between gonadotrophins are limited. What we were interested in is their economic value. The actual cost in euros or dollars differs widely between countries and therefore our focus was on the resource use that determines eventual cost differences. This resource use was expressed as amount of IU used. Therefore, we systematically examined the evidence on the total amount of recombinant and highly purified urinary-derived gonadotropins required to reach a 
Materials and Methods
The review is reported according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). The protocol for this systematic review is registered in the Prospective Register of Systematic Reviews (PROSPERO) in April 2016 (Registration: Prospero CRD42016038238, available from http://www.crd.york.ac.uk/ PROSPERO/display_record.asp?ID=CRD42016038238).
Literature search
We conducted a literature search in the databases Medline, Embase and CINAHL up to July 2018. We used the same search terms as the Cochrane review on the effectiveness of recombinant FSH versus urinary-derived gonadotrophins (van Wely et al., 2011) (Supplementary data).
Inclusion criteria and study selection
We screened all records for eligibility by analyzing the title and abstract. We included randomized controlled trials comparing rFSH with HPhMG or HP-FSH for ovarian stimulation in couples with an indication for IVF or ICSI treatment. We excluded studies that compared rFSH with hMG or pituitary extract-FSH, because these products are no longer available for ovarian stimulation. There was no language restriction. After the eligibility screening we analyzed the studies by reading the full text. The studies were selected by two reviewers (E.B. and M.W.).
Data extraction and outcomes
We extracted data on female age, previous ART cycles, the number of women in each study arm, intervention details such as agonist or antagonist use, total amount of gonadotrophins in IU per woman who started an IVF/ICSI cycle, clinical pregnancy, live birth, cumulative live birth following fresh and cryocycles and funding per included study. An overview of study characteristics is shown in Table I . Some trials reported the total number of ampoules used. We transformed this data into the amount of gonadotrophins in IU. Our primary outcome was the total amount of gonadotrophins in IU per woman who started an IVF/ICSI cycle required per live birth. Secondary outcomes were the total amount of gonadotrophins in IU per woman who started IVF/ICSI cycle, clinical pregnancy, cumulative live birth following fresh and cryocycles and oocytes retrieved.
In our protocol (Prospero CRD42016038238) we intended to report duration of stimulation. Although we did evaluate this outcome we decided not to present this analysis, since some days more or less stimulation time does not represent resource use, while total amount of gonadotropins used does.
Assessment of study quality
To check the quality of the article we used the risk of bias tool created by the Cochrane Collaboration (Cochrane Handbook). We looked at the following six domains: randomization sequence generation, allocation concealment, performance and detection bias, completeness of outcome data, selective outcome reporting and other potential sources. Risk of bias per study was expressed in the methodological 
Statistical analysis
We retrieved for each individual study means and SD for the total amount of gonadotrophins per woman who started an IVF/ICSI cycle. We tried to retrieve these data and data on clinical pregnancy, live birth and cumulative live birth following fresh and cryocycles per woman treated with gonadotrophins. The outcomes were summarized by calculating the individual and pooled mean difference (MD) or relative risk (RR) with 95% CI for rFSH versus HP-hMG and rFSH versus HP-FSH. We used the Review Manager software (Review Manager [RevMan] Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014) to perform these metaanalyses. Presence of heterogeneity was assessed by the I 2 statistic. An I 2 >50% was taken to indicate substantial heterogeneity. We 
Results

Search
We identified 362 records and hand searching resulted in another 11 records. After we removed the duplications, there were 348 records to screen for title and abstract. We excluded 302 records based on the inclusion and exclusion criteria. We assessed a total of 46 articles for eligibility by reading the full text after which we excluded another 18 studies expressing 19 comparisons. A summary of the search is presented in a flow diagram (Fig. 1) .
Included studies
We included the 28 studies that met all selection criteria in the review. The total number of women was 7553. Seven studies compared rFSH with HP-hMG (n = 3397) and all provided data on the amount of gonadotrophin used. In total, 3220 women (95%) actually had started gonadotrophin treatment. Twenty-one studies compared rFSH with HP-FSH (n = 4156), but only 17 (n = 3775) provided data on amount of gonadotrophin used. In total, 3629 women (96%) actually had started gonadotrophin treatment. The studies varied in terms of female age, previous ART cycles, starting dose, downregulation protocol, fertilization method, number of embryo transfers and funding. The characteristics of each study can be found in Table I .
Assessment of study quality
The results of the assessment of the risks of bias using the Cochrane tool are summarized in Figs 2 and 3. The quality of the studies varied between low and high. Older studies performed before 2000 were more likely to be of lower quality. Five studies were only available as an abstract, all comparing rFSH versus HP-FSH (Ferraretti et al., 1999; Gallego et al., 2003; Germond et al., 2000; Ghosh et al., 1999; O'Dea et al., 1993) . We considered these five studies to be of low quality, mainly due to incomplete outcomes, reporting bias and uncertainty about selection bias and other forms of bias.
In two studies we could not determine whether the data were intention-to-treat or not (Gallego et al., 2003; Liu et al., 2015) . None of the trials used double blinding. Although double blinding is unlikely to have impact on pregnancy outcomes, it might have biased the outcome gonadotrophin amount.
Outcomes
Amount of gonadotrophins per woman that started IVF/ICSI cycle
Of the seven trials comparing rFSH with HP-hMG, three trials found no evidence of a difference in the amount of gonadotrophins, one found that more rFSH was required and three trials found that less rFSH was required. Pooling the data, we found no evidence of a difference in the amount of gonadotrophins (seven studies; N = 3220; MD, −37 IU; 95% CI, −115 to 41; I 2 = 68%; low quality of evidence) (Fig. 4a) .
Of the 17 trials comparing rFSH with HP-FSH, seven trials found no evidence of a difference in the amount of gonadotrophins, three found that more rFSH was required and seven found that less rFSH was required. Pooling the data, we found no evidence of a difference in the amount of gonadotrophins (17 studies; N = 3629; MD −31 IU; 95% CI, −290 to 228; I 2 = 97%; low quality of evidence) (Fig. 4b) . For both comparisons there was severe statistical heterogeneity.
Pregnancy outcomes
Of the seven trials comparing rFSH and HP-hMG, all trials had data on clinical pregnancy and live birth rate and three trials (N = 2109) had data on cumulative live births following fresh and cryo-embryo transfers (Fig. 5) .
We found a slightly lower clinical pregnancy rate and live birth rate in the rFSH-treated women than in the HP-hMG-treated women (seven studies, N= 3397. Clinical pregnancy: RR, 0.90; 95% CI, 0.81-1.00. Live birth: RR, 0.88; 95% CI, 0.78-0.99; high quality of evidence). We found insufficient evidence of a difference in cumulative live birth rate (three studies, N = 2109. Cumulative live birth: RR, 0.91; 95% CI, 0.80-1.04). There was no indication of heterogeneity for these outcomes across studies (I 2 = 0%, high quality of evidence).
Of the 21 trials comparing rFSH and HP-FSH, all trials had data on clinical pregnancy rate and 12 trials had data on live birth rate (Fig. 6) . One trial had data on cumulative ongoing pregnancies following frozenthawed embryo transfers (Out et al., 1995) , but no trials had data on cumulative live birth rate.
We found little or no difference in clinical pregnancy rate nor in live birth rate in the rFSH-treated women compared to HP-FSH-treated women (21 studies, N = 4165. Clinical pregnancy: RR, 1.03; 95% CI, 0.94-1.13. Twelve studies, N = 2458. Live birth: RR, 1.03; 95% CI, 0.90-1.18). There was no indication of heterogeneity across studies (I 2 = 0%, high quality of evidence). 
Required amount to reach a clinical pregnancy
Comparingv rFSH with HP-hMG, we found that the required amount to achieve a clinical pregnancy was 7168 IU (95% CI, 5007 to 9330) for rFSH and 5774 IU (95% CI, 4061 to 7488) for HP-hMG. The difference in mean gonadotrophin amount per extra clinical pregnancy was 720 IU (95% CI, −29 to 1470) for rFSH versus HP-hMG (Fig. 7) .
Comparing rFSH with HP-FSH, we found that the required amount to achieve a clinical pregnancy was 8017 IU (95% CI, 6714 to 9320) for rFSH and 9079 IU (95% CI, 7297 to 10861) for HP-FSH. The difference in mean gonadotrophin amount per extra clinical pregnancy was −380 IU (95% CI, −1778 to 1017) for rFSH versus HP-FSH (Fig. 7) . 
Required amount to reach a live birth
Comparing rFSH with HP-hMG, we found that the required amount to achieve a live birth was 8222 IU (95% CI, 5743 to 10 703) for rFSH and 6548 IU (95% CI, 4605 to 8491) for HP-hMG. The difference in mean gonadotrophin amount per extra live birth was 789 IU (95% CI, −9.5 to 1570) for rFSH versus HP-hMG (Fig. 7) . In the three trials with data on cumulative live births the difference in mean gonadotrophin amount per extra live birth was 310 IU (95% CI, −158 to 778) for rFSH versus HP-hMG.
Comparing rFSH with HP-FSH, we found that the required amount to achieve a live birth was 9880 IU (95% CI, 8080 to 11489) for rFSH (Fig. 7) .
Required amount for one more oocyte
Of the seven trials comparing rFSH and HP-hMG, all trials had data on the number of oocytes retrieved. Of the 21 trials comparing rFSH and HP-FSH, all trials had data on the number of oocytes retrieved. MD in number of oocytes retrieved was 1.83 (95% CI, 1.20 to 2.64; N = 3397; I 2 = 70%; low quality evidence) for rFSH versus HP-HMG and was −0.57 (95% CI, −0.20 to 1.33; N = 2458; I 2 = 80%; low quality evidence) for rFSH versus HP-FSH.
Comparing rFSH with HP-HMG, we found that the required amount per oocyte retrieved was 198 IU (95% CI, -38 to 433) for rFSH and 230 IU (95% CI, 107 to 352) for HP-HMG. The estimated difference in mean gonadotrophin amount per extra oocyte was -50 IU (95% CI, -276 to 226) for rFSH versus HP-FSH.
Comparing rFSH with HP-FSH, we found that the required amount per oocyte retrieved was 260 IU (95% CI, 17 to 503) for rFSH and 286 IU (95% CI, 153 to 418) for HP-FSH. The estimated difference in mean gonadotrophin amount per oocyte was −18 IU (95% CI, −322 to 304) for rFSH versus HP-FSH.
In all comparisons both oocyte number and amount of gonadotrophin differed across studies, creating severe statistical heterogeneity. This limits the external validity of the estimated required amount of gonadotrophin for one more oocyte presented here.
Discussion
In this systematic review and meta-analysis we evaluated the evidence on the total amount of gonadotrophins required to reach a live birth after ovarian stimulation with rFSH in comparison to HP-hMG or HP-FSH in couples undergoing IVF or ICSI treatment. We found no The main strength of our study is that we were able to collect data for 7553 women from studies with a strong design. Also, the results are applicable to a general IVF/ICSI population and are important from a social-economic perspective.
A limitation lies in the severe clinical heterogeneity in mean total amount of gonadotrophins used across individual studies. Study year and country could partly explain this heterogeneity. Older studies often used higher starting doses.
Not all studies reported early drop outs, and for those studies we can thus not be certain that all women started gonadotrophin treatment. This might have affected the averaged total amount of gonadotrophins.
A further limitation of our review is that we did not evaluate potential differences in patient characteristics such as female age and indication for IVF. These factors could influence resource use. To take these differences into account an individual participant data meta-analysis would be necessary.
In our meta-analysis we focused on the total amount of gonadotrophins required to reach a clinical pregnancy. Previous metaanalyses focused on the effectiveness and safety of the different types of gonadotrophin (Coomarasamy et al., 2008; Al-Inany et al., 2009; van Wely et al., 2011; Gerli et al., 2013) . These meta-analyses suggested that HP-hMG results in slightly more clinical pregnancies and live births than rFSH, possibly due to the LH activity in HP-hMG, but the relation to the required gonadotrophin amount per live birth was not studied.
We consider the required gonadotrophin amount per clinical pregnancy or per live birth to be representative of the biopotency of a gonadotrophin. A more biopotent product would require a lower total dose and less stimulation days in comparison to a less biopotent product. In general, basic FSH isoforms, such as rFSH, have a higher receptor affinity in vitro compared to more acid isoforms, such as HP-hMG and HP-FSH, but more acid isoforms have a longer plasma half-life compared to basic FSH isoforms. There has been much discussion on the presumed differences in biopotency of the various gonadotrophins related to isoform composition and acidity. Some studies describe that it is unknown whether these differences influence biopotency (Practice Committee of American Society for Reproductive Medicine, Birmingham, Alabama, 2008; Smitz et al., 2016) , while others suggest that in view of the higher biopotency in vitro, rFSH might also be more biopotent in vivo (Barrios-De-Tomasi et al., 2002; Andersen et al., 2004; Andersen and Ezcurra, 2011) , and one study suggests that, because of the longer plasma half-lives, more acid isoforms have an higher in vivo bioactivity (Wolfenson et al., 2005) .
It can be argued that gonadotrophin amount per oocyte would better represent biopotency. Although not pre-defined, we added this outcome to our analysis and found insufficient evidence of a difference between rFSH and HP-HMG, and rFSH and HP-FSH. This analysis was hampered by the heterogeneity in the data.
Our results suggest that, although rFSH, HP-hMG and HP-FSH differ in isoform composition and acidity, as well as in LH activity, these gonadotrophins have a comparable biopotency.
We conclude that the differences in required amount of gonadotrophin to reach a live birth between rFSH, HP-hMG and HP-FSH are small. Decision-making should thus be based on convenience, availability, actual costs and patient preferences.
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Supplementary data are available at Human Reproduction Open online. 
